PD-1 and PD-l1 antibodies for melanoma

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3111-3116

  Tsai, Katy K ^a   Zarzoso, Inés ^a   Daud, Adil I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BMS 936559; Immunotherapy; Melanoma; MPDL3280A; Nivolumab; PD 1; PD L1; PD L2; Pembrolizumab

Indexed keywords

AMP 224; AMP 514; BMS 936559; BMS 986016; CARBOPLATIN; COBIMETINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; DURVALUMAB; GLYCOPROTEIN GP 100; INTERLEUKIN 21; IPILIMUMAB; LIRILUMAB; MONOCLONAL ANTIBODY; MONTANIDE ISA 51; MPDL 3280A; MSB 0010718C; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PIDILIZUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ADVANCED CANCER; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE HEPATITIS; CANCER IMMUNOTHERAPY; COLITIS; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DIARRHEA; DRUG DESIGN; DRUG FATALITY; DRUG TARGETING; FATIGUE; HEMATOLOGIC MALIGNANCY; HEPATITIS; HUMAN; IMMUNOREGULATION; LIVER TOXICITY; LYMPHOCYTE PROLIFERATION; MACULOPAPULAR RASH; MELANOMA; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PROCEDURES; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84921807024     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.983409     Document Type: Article

References (31)

1. The concept of immunological surveillance. [Prog Exp Tumor Res. 1970] - PubMed - NCBI [Internet]. [cited 2014 Oct 23]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/4921480?dopt=Abstract&holding=f1000,f1000m,isrctnucsflib%26tool%3Dcdl%26otool%3Dcdlotool
2. Strausberg RL. Tumor microenvironments, the immune system and cancer survival. Genome Biol 2005; 6:211; PMID:15774034; http://dx.doi.org/10.1186/gb-2005-6-3-211
3. Babcock SK, Gill RG, Bellgrau D, Lafferty KJ. Studies on the two-signal model for T cell activation in vivo. Transplant Proc 1987; 19:303-6; PMID:3103279
4. Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, Tamada K, Pardoll DM, Chen L. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 2007; 110:180-5; PMID:17289811; http://dx.doi.org/10.1182/blood-2006-11-060087
5. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
6. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
7. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013; 1291:1-13; PMID:23772560; http://dx.doi.org/10.1111/nyas.12180
8. Krummel MF, Allison JP. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995. 182: 459-465. J Immunol 2011; 187:3459-65; PMID:7543139; http://dx.doi.org/10.1084/jem.182.2.459
9. Hwang KW, Sweatt WB, Mashayekhi M, Palucki DA, Sattar H, Chuang E, Alegre M-L. Transgenic expression of CTLA-4 controls lymphoproliferation in IL-2-deficient mice. J Immunol 2004; 173:5415-24; PMID:15494488; http://dx.doi.org/10.4049/jimmunol.173.9.5415
10. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
11. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain J-F, Testori A, Grob J-J, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
12. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-95; PMID:1396582
13. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013; 14:1212-8; PMID:24240160; http://dx.doi.org/10.1038/ni.2762
14. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2:116-26; PMID:11910893; http://dx.doi.org/10.1038/nri727
15. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
16. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261-8; PMID:11224527; http://dx.doi.org/10.1038/85330
17. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169:5538-45; PMID:12421930; http://dx.doi.org/10.4049/jimmunol.169.10.5538
18. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17; PMID:8558223
19. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907-13; PMID:8120958; http://dx.doi.org/10.1001/jama.1994.03510360033032
20. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116:1757-66; PMID:20143437; http://dx.doi.org/10.1002/cncr.24899
21. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
22. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
23. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
24. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
25. Atkins MB, Kudchadkar RR, Sznol M, McDermott DF, Lotem M, Schachter J, Wolchok JD, Urba WJ, Kuzel T, Schuchter LM, et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. J Clin Oncol [Internet] 2014 [cited 2014 Oct 27]; 32:5s. Available from: http://meetinglibrary.asco.org/content/131463-144; PMID:; http://dx.doi.org/10.1200/JCO.2014.56.5424
26. Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria JC, Hamid O, Powderly JD, Burris HA, Mokatrin A, Kowanetz M, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. ASCO Meeting Abstracts 2013; 31:3000
27. Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J Clin Oncol [Internet] 2013 [cited 2014 Oct 27]; 31. Available from: http://meetinglibrary.asco.org/content/113277-132; PMID:
28. Daud A, Hamid, Omid, Ribas, Antoni. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PDL1 expression with outcome. AACR Presentation Abstract CT104 2014
29. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, et al. Nivolumab plus Ipilimumab in Advanced Melanoma. New Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
30. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu W-J, Gangadhar TC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
31. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694